Quantinno Capital Management LP Buys 72,900 Shares of Alignment Healthcare, Inc. $ALHC

Quantinno Capital Management LP increased its position in shares of Alignment Healthcare, Inc. (NASDAQ:ALHCFree Report) by 442.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 89,387 shares of the company’s stock after purchasing an additional 72,900 shares during the period. Quantinno Capital Management LP’s holdings in Alignment Healthcare were worth $1,575,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Summit Securities Group LLC purchased a new stake in shares of Alignment Healthcare in the 4th quarter worth approximately $26,000. Parallel Advisors LLC grew its stake in shares of Alignment Healthcare by 87.7% during the fourth quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock worth $33,000 after acquiring an additional 773 shares during the last quarter. Larson Financial Group LLC acquired a new position in shares of Alignment Healthcare during the third quarter valued at about $33,000. First Horizon Corp purchased a new position in shares of Alignment Healthcare in the 4th quarter valued at approximately $39,000. Finally, Signature Equity Partners LLC acquired a new stake in Alignment Healthcare in the 1st quarter worth approximately $46,000. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Insider Activity at Alignment Healthcare

In other Alignment Healthcare news, CEO John E. Kao sold 298,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $13.88, for a total transaction of $4,136,240.00. Following the completion of the sale, the chief executive officer directly owned 790,766 shares in the company, valued at approximately $10,975,832.08. The trade was a 27.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $19.55, for a total value of $586,500.00. Following the completion of the transaction, the president owned 947,313 shares in the company, valued at approximately $18,519,969.15. This trade represents a 3.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,039,951 shares of company stock worth $19,079,987 in the last quarter. Corporate insiders own 5.20% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. KeyCorp restated an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Zacks Research lowered Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. TD Cowen reaffirmed a “buy” rating on shares of Alignment Healthcare in a research note on Monday, August 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Alignment Healthcare in a report on Tuesday, August 4th. Finally, Wall Street Zen downgraded shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

Read Our Latest Stock Report on ALHC

Alignment Healthcare News Roundup

Here are the key news stories impacting Alignment Healthcare this week:

  • Positive Sentiment: An analyst upgrade argued that Alignment’s valuation drawdown has created potential upside. The company’s second-quarter performance included 31% membership growth, a record-low medical benefits ratio, 48% adjusted EBITDA growth and increased full-year guidance. Alignment Healthcare: The Drawdown I Told You To Wait For Has Arrived
  • Positive Sentiment: Recent quarterly results remain a fundamental support: Alignment reported earnings of $0.17 per share versus the $0.13 consensus estimate, while revenue rose 31.6% year over year to $1.34 billion. Analysts maintain a “Moderate Buy” consensus, with an average price target of $23.60.
  • Neutral Sentiment: Institutional ownership is substantial at 86.19%, and several major investors recently increased or initiated positions. However, this support has not prevented the shares from trading near recent lows.
  • Negative Sentiment: Multiple law firms, including Kaplan Fox, Frank R. Cruz and Pomerantz, announced investigations into possible securities-law violations and potential investor claims. The reports reference a 16% share-price decline on July 8 and allegations tied to possible financial manipulation. These are investigations and allegations, not established findings, but they add significant legal and reputational risk. Securities Fraud Investigation Into Alignment Healthcare Continues
  • Negative Sentiment: Chief Executive Officer John Kao sold 298,000 shares worth approximately $4.1 million, reducing his direct ownership by 27.37%. The transaction was executed under a pre-arranged Rule 10b5-1 plan, which lessens—but does not eliminate—the negative signaling effect for investors. Alignment Healthcare Insider Trading

Alignment Healthcare Stock Up 2.4%

Shares of NASDAQ ALHC opened at $13.52 on Thursday. The company’s 50-day simple moving average is $19.49 and its 200-day simple moving average is $19.26. Alignment Healthcare, Inc. has a 52-week low of $13.05 and a 52-week high of $25.12. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 71.16 and a beta of 1.10. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 1.22.

Alignment Healthcare (NASDAQ:ALHCGet Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04. The business had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The company’s quarterly revenue was up 31.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.07 earnings per share. Equities analysts predict that Alignment Healthcare, Inc. will post 0.17 EPS for the current fiscal year.

Alignment Healthcare Company Profile

(Free Report)

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.

See Also

Want to see what other hedge funds are holding ALHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alignment Healthcare, Inc. (NASDAQ:ALHCFree Report).

Institutional Ownership by Quarter for Alignment Healthcare (NASDAQ:ALHC)

Receive News & Ratings for Alignment Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alignment Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.